Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling

BACKGROUND: Cardiac remodeling is one of the major risk factors for heart failure. In patients with type 2 diabetes, sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of the first hospitalization for heart failure, possibly through glucose-independent mechanisms in part, but the unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuze, Lin, Xiaoyan, Chu, Yong, Chen, Xiaoming, Du, Heng, Zhang, Hailin, Xu, Changsheng, Xie, Hong, Ruan, Qinyun, Lin, Jinxiu, Liu, Jie, Zeng, Jinzhang, Ma, Ke, Chai, Dajun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196449/
https://www.ncbi.nlm.nih.gov/pubmed/34116674
http://dx.doi.org/10.1186/s12933-021-01312-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196449/
https://www.ncbi.nlm.nih.gov/pubmed/34116674
http://dx.doi.org/10.1186/s12933-021-01312-8

Ejemplares similares